Most Recent Articles about GSK
https://www.zacks.com/commentary/2261192/top-stock-reports-for-danaher-regeneron-pharmaceuticals-palo-alto-networks?cid=CS-ZC-FT-research_daily-2261192
Apr 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
zc:817260156667333572
0
https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559
Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
zc:6541030334554079037
0
https://www.zacks.com/stock/news/2258816/why-the-market-dipped-but-gsk-gsk-gained-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2258816
Apr 19, 2024 - In the latest trading session, GSK (GSK) closed at $39.75, marking a +1.22% move from the previous day.
zc:1618234255153817694
0